CL2011000363A1 - Metodo para identificar predisposicion a hepatotoxicidad mediante el alelo hla dqa1*0102, drb1*1501, dqb1*0602, drb5*0101; uso de sonda que detecta el alelo para determinar la susceptibilidad a desarrollar hepatotoxicidad luego de administrar lumiracobix; uso de lumiracobix para tratamiento de trastornos mediados por cox-2. - Google Patents
Metodo para identificar predisposicion a hepatotoxicidad mediante el alelo hla dqa1*0102, drb1*1501, dqb1*0602, drb5*0101; uso de sonda que detecta el alelo para determinar la susceptibilidad a desarrollar hepatotoxicidad luego de administrar lumiracobix; uso de lumiracobix para tratamiento de trastornos mediados por cox-2.Info
- Publication number
- CL2011000363A1 CL2011000363A1 CL2011000363A CL2011000363A CL2011000363A1 CL 2011000363 A1 CL2011000363 A1 CL 2011000363A1 CL 2011000363 A CL2011000363 A CL 2011000363A CL 2011000363 A CL2011000363 A CL 2011000363A CL 2011000363 A1 CL2011000363 A1 CL 2011000363A1
- Authority
- CL
- Chile
- Prior art keywords
- lumiracobix
- hepatotoxicity
- allele
- drb5
- dqb1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
Abstract
Método para identificar predisposición a hepatotoxicidad mediante el alelo hla dqa1*0102, drb1*1501, dqb1*0602, drb5*0101; uso de sonda que detecta el alelo para determinar la susceptibilidad a desarrollar hepatotoxicidad luego de administrar lumiracobix; uso de lumiracobix para tratamiento de trastornos mediados por cox-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9108108P | 2008-08-22 | 2008-08-22 | |
US21169809P | 2009-04-02 | 2009-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000363A1 true CL2011000363A1 (es) | 2011-07-01 |
Family
ID=41381812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000363A CL2011000363A1 (es) | 2008-08-22 | 2011-02-21 | Metodo para identificar predisposicion a hepatotoxicidad mediante el alelo hla dqa1*0102, drb1*1501, dqb1*0602, drb5*0101; uso de sonda que detecta el alelo para determinar la susceptibilidad a desarrollar hepatotoxicidad luego de administrar lumiracobix; uso de lumiracobix para tratamiento de trastornos mediados por cox-2. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110144206A1 (es) |
EP (1) | EP2318545A1 (es) |
JP (1) | JP2012500630A (es) |
KR (1) | KR20110055682A (es) |
CN (1) | CN102197144A (es) |
AU (1) | AU2009282901A1 (es) |
BR (1) | BRPI0917796A2 (es) |
CA (1) | CA2735677A1 (es) |
CL (1) | CL2011000363A1 (es) |
IL (1) | IL211225A0 (es) |
MA (1) | MA32645B1 (es) |
MX (1) | MX2011001968A (es) |
TW (1) | TW201020547A (es) |
WO (1) | WO2010022211A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3003304A1 (en) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Viral neoepitopes and uses thereof |
CN115154476B (zh) * | 2020-04-20 | 2023-10-27 | 中南大学 | 青钱柳的提取物及其抗痛风和降尿酸应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2239429C2 (ru) * | 1996-10-15 | 2004-11-10 | Джи. Ди. Сирл Энд Ко. | Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии |
PE20020351A1 (es) * | 2000-09-11 | 2002-06-14 | Novartis Ag | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 |
JP2007117085A (ja) * | 2005-09-28 | 2007-05-17 | Genodive Pharma Kk | 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法 |
-
2009
- 2009-08-20 CA CA2735677A patent/CA2735677A1/en not_active Abandoned
- 2009-08-20 JP JP2011523980A patent/JP2012500630A/ja active Pending
- 2009-08-20 TW TW098128062A patent/TW201020547A/zh unknown
- 2009-08-20 US US13/060,137 patent/US20110144206A1/en not_active Abandoned
- 2009-08-20 AU AU2009282901A patent/AU2009282901A1/en not_active Abandoned
- 2009-08-20 EP EP09791710A patent/EP2318545A1/en not_active Withdrawn
- 2009-08-20 WO PCT/US2009/054415 patent/WO2010022211A1/en active Application Filing
- 2009-08-20 KR KR1020117006420A patent/KR20110055682A/ko not_active Application Discontinuation
- 2009-08-20 MX MX2011001968A patent/MX2011001968A/es not_active Application Discontinuation
- 2009-08-20 BR BRPI0917796A patent/BRPI0917796A2/pt not_active Application Discontinuation
- 2009-08-20 CN CN2009801418233A patent/CN102197144A/zh active Pending
-
2011
- 2011-02-14 IL IL211225A patent/IL211225A0/en unknown
- 2011-02-21 CL CL2011000363A patent/CL2011000363A1/es unknown
- 2011-03-18 MA MA33713A patent/MA32645B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009282901A1 (en) | 2010-02-25 |
IL211225A0 (en) | 2011-04-28 |
CN102197144A (zh) | 2011-09-21 |
EP2318545A1 (en) | 2011-05-11 |
CA2735677A1 (en) | 2010-02-25 |
MA32645B1 (fr) | 2011-09-01 |
BRPI0917796A2 (pt) | 2016-03-01 |
TW201020547A (en) | 2010-06-01 |
MX2011001968A (es) | 2011-03-21 |
US20110144206A1 (en) | 2011-06-16 |
WO2010022211A1 (en) | 2010-02-25 |
KR20110055682A (ko) | 2011-05-25 |
JP2012500630A (ja) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
BR112014010955A2 (pt) | sistema e método para processar amostras | |
EA201600085A1 (ru) | Набор для обнаружения соевого события syht0h2 | |
BRPI0812772A2 (pt) | Método in vitro para a identificação de moléculas antigênicas transportadas por eritrócitos e/ou anticorpos anti-eritrocitários de um indivíduo, método para combinação cruzada de eritrócitos que devem ser transfundidos em um paciente e um conjunto de reagentes para a execução do método de detecção . | |
BRPI0819517A2 (pt) | "método para detectar a presença de um microorganismo alvo em uma amostra" | |
BR112013020773A8 (pt) | método para a detecção localizada in situ de rna, método para a determinação da presença e da localização de uma sequência genética, conjunto de sondas em cadeado, uso do conjunto de sondas, kit e método para a identificação de uma célula | |
MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
BR112016028944A2 (pt) | kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção | |
BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
ATE493290T1 (de) | Alcotestgerät | |
BR112012020251A2 (pt) | dispositivo de análise para a aquisição de amostra, tratamento e reação | |
UY32225A (es) | Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2 | |
CO6710946A2 (es) | Método para activar células t auxiliares | |
ATE509123T1 (de) | Hochauflösende hochdurchsatz-hla-genotypisierung mittels klonaler sequenzierung | |
CL2011003129A1 (es) | Procedimiento para determinar riesgo de padecer enfermedad cardiovascular que comprende determinar la presencia de polimorfismos de un solo nucleotido (snp) | |
BRPI0915979A2 (pt) | Métodos para melhorar a qualidade de vida de um animal, para aumentar a qualidade de vida de um animal, para tratar um animal sofrendo de um distúrbio ou doença, para medir o aumento na qualidade de vida de um animal, e para identificar um animal que pode se beneficiar da alimentação com uma composição de ração, e, kit. | |
BR112016029521A2 (pt) | ?kit, dispositivo e método para a detecção de câncer de estômago? | |
MY150648A (en) | Hla alleles associated with adverse drug reactions and methods for detecting such | |
BR112012026536A2 (pt) | sistemas e métodos para predizer deficiência gastrointestinal | |
BRPI0811356A2 (pt) | Métodos para determinar a concentração de um polímero ou oligômero aniônicos | |
BR112019006879A2 (pt) | sistema de análise e método para testagem de uma amostra | |
BR112014004929A2 (pt) | conversão de unidades de alquilação de hf para processos de alquilação catalisada por líquido iônico | |
BR112012015583A2 (pt) | métodos para purificação de cucurbiturila | |
BRPI0702163A (pt) | composições de toner e métodos | |
BR112016019740A2 (pt) | monitoramento do estado de inflamação |